World journal of urology · 2025
The effect of race/ethnicity on systemic chemotherapy in urothelial carcinoma patients exposed to radiotherapy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
de Angelis Mario, Siech Carolin, Di Bello Francesco, Peñaranda Natali Rodriguez, Goyal Jordan A, Tian Zhe, Longo Nicola, Chun Felix K H, Micali Salvatore, Saad Fred, Shariat Shahrokh F, Jannello Letizia Maria Ippolita, Longoni Mattia, Musi Gennaro, Gandaglia Giorgio, Moschini Marco, Montorsi Francesco, Briganti Alberto, Karakiewicz Pierre I
Аннотация
INTRODUCTION: Based on prospective trials' result, it is unknown whether race/ethnicity affects the magnitude of cancer-specific survival differences after trimodal therapy (TMT) versus external beam radiation therapy alone (EBRT) for urothelial carcinoma for urinary bladder (UCUB). We addressed this knowledge gap.
MATERIALS AND METHODS: Within the Surveillance, Epidemiology, and End Results database (2004-2020), we identified patients with cT2-T4aN0M0 UCUB treated with either TMT or EBRT. We focused on the four most prevalent race/ethnicities: Caucasians, Hispanics, African American (AAs) and Asian/Pacific Islanders (APIs). Cumulative incidence plots and multivariable competing risks regression (CRR) models addressed cancer specific mortality (CSM) after additional adjustment for other-cause mortality (OCM) and standard covariates.
RESULTS: Of 3249 patients, 2643 (81%) were Caucasians versus 254 (8%) AAs versus 209 (7%) Hispanics versus 143 (4%) APIs. Compared to EBRT, TMT rates were higher in Caucasians (81%) and APIs (81%), lower in AAs (75%) and lowest in Hispanics (69%). In Caucasians, five-year CSM rates were 41.6% after TMT versus 49.0% after EBRT and TMT independently predicted lower CSM (HR: 0.70, p < 0.001). In AAs, Hispanics and APIs, TMT did not predict CSM differences (p = 0.1, 0.2 and p = 0.06, respectively).
CONCLUSION: For Caucasians UCUB patients, TMT is strongly associated with significantly lower CSM. However, this observation cannot be generalized non-Caucasian subgroups, where TMT did not predict lower CSM relative to EBRT.
MATERIALS AND METHODS: Within the Surveillance, Epidemiology, and End Results database (2004-2020), we identified patients with cT2-T4aN0M0 UCUB treated with either TMT or EBRT. We focused on the four most prevalent race/ethnicities: Caucasians, Hispanics, African American (AAs) and Asian/Pacific Islanders (APIs). Cumulative incidence plots and multivariable competing risks regression (CRR) models addressed cancer specific mortality (CSM) after additional adjustment for other-cause mortality (OCM) and standard covariates.
RESULTS: Of 3249 patients, 2643 (81%) were Caucasians versus 254 (8%) AAs versus 209 (7%) Hispanics versus 143 (4%) APIs. Compared to EBRT, TMT rates were higher in Caucasians (81%) and APIs (81%), lower in AAs (75%) and lowest in Hispanics (69%). In Caucasians, five-year CSM rates were 41.6% after TMT versus 49.0% after EBRT and TMT independently predicted lower CSM (HR: 0.70, p < 0.001). In AAs, Hispanics and APIs, TMT did not predict CSM differences (p = 0.1, 0.2 and p = 0.06, respectively).
CONCLUSION: For Caucasians UCUB patients, TMT is strongly associated with significantly lower CSM. However, this observation cannot be generalized non-Caucasian subgroups, where TMT did not predict lower CSM relative to EBRT.